Evidence map›Paper›PMID 39723092›Full record

ArticleFood science & nutrition2024

Evaluation of the Potential Targets of Shenxian-Shengmai Oral Liquid in Treating Sick Sinus Syndrome Based on Network Pharmacology and Molecular Docking.

Ping Hou, Heng Zhang, Dong-Yu Min, Jie Wu, Chen Chen, Jie Wang, Yong-Ping Lu, Ying-Jia Yao, Ling-Kang Li, Yue Liu

Abstract read
In one paragraph

Article in Food science & nutrition, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ping HouGraduate School Liaoning University of Traditional Chinese Medicine Shenyang Liaoning China.
Heng ZhangDepartment of Rehabilitation Medicine Shandong Provincial Hospital Affiliated to Shandong First Medical University Jinan Shandong China.
Dong-Yu MinExperimental Center of Traditional Chinese Medicine Affiliated Hospital of Liaoning University of Traditional Chinese Medicine Shenyang Liaoning China.
Jie WuSchool of Public Health Shenyang Medical College Shenyang Liaoning China.
Chen ChenGraduate School Liaoning University of Traditional Chinese Medicine Shenyang Liaoning China.
Jie WangSchool of Traditional Chinese Medicine Shenyang Medical College Shenyang Liaoning China.
Yong-Ping LuDepartment of NHC Key Laboratory of Reproductive Health and Medical Genetics Liaoning Research Institute of Family Planning (The Affiliated Reproductive Hospital of China Medical University) Shenyang Liaoning China.
Ying-Jia YaoCollege of Life and Health Sciences Northeastern University Shenyang Liaoning China.
Ling-Kang LiGraduate School Liaoning University of Traditional Chinese Medicine Shenyang Liaoning China.
Yue LiuSchool of Traditional Chinese Medicine Shenyang Medical College Shenyang Liaoning China.ORCID https://orcid.org/0009-0000-7296-9011

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Shenxian-Shengmai (SXSM) is a Chinese patent medicine used in the treatment of sick sinus syndrome (SSS). However, its active chemical compounds and the underlying molecular mechanisms remain unclear. In this study, we researched the underlying mechanisms of SXSM in treating SSS. We conducted network analysis and molecular docking to identify the small molecules and core targets responsible for the therapeutic efficacy of SXSM on SSS. In vitro experiments were performed to verify the potential therapeutic mechanism. Network pharmacological analysis identified 17 core targets. Among these, BMP4, KCNH2, KCNMA1, and KCNQ1 were identified to be involved in various biological processes, such as the formation and regulation of the cardiac pacemaking system and potassium ion transmembrane transport. The experimental analysis revealed that SXSM could upregulate the expression of the

Indexed as

BMP4molecular dockingnetwork pharmacologypotassium ion channelsick sinus syndrome

Identifiers

PMID39723092
PMCPMC11666830

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.